SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA Breakthrough Therapy Designation for its drug targeting a rare disease, Sanfilippo syndrome type B. The community is discussing the potential for continued gains, a possible short squeeze, and comparing it to other high-flying stocks. Some traders express caution, pointing to the company's financials and the potential for a pullback, while others are excited about the long-term potential.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Siyata Mobile Inc

Siyata Mobile ($SYTA) is trending as it finalizes its merger with Core Gaming, set to trade under the ticker $CHAI next week, which has spurred discussion around the reverse stock split and its potential impact. The community is actively debating the valuation of the combined entity, the lock-up period for major shareholders, and the possibility of a squeeze. Some traders are optimistic about the AI-driven mobile gaming and app platform's future, while others express concerns about dilution and historical performance.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to its recent NASDAQ listing and a partnership with a major Korean payment processor, sparking community discussion about its potential in quantum-secure stablecoin settlements.  Some investors are drawing comparisons to other quantum computing stocks and suggesting BTQ is undervalued, while others express concern about revenue and potential dilution. The community is closely watching for increased institutional and retail investor attention.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp ($LAES) is trending due to significant premarket hype and discussions around potential breakouts, with community members eyeing targets as high as $10. Conversations highlight the company's upcoming chip launch and its positioning in the quantum computing sector alongside names like $NVDA and $QBTS. Some caution about potential dilution, while others express strong bullish sentiment, anticipating a short squeeze and parabolic continuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending due to speculation around potential U.S. government investment in its Greenland rare earth project, fueled by a Reuters report, though a White House denial has created volatility. Community members are debating the validity of the reports and the broader implications for the company's future, with some viewing it as a strategic play for U.S. resource independence. The stock's price movement and high trading volume reflect the uncertainty and heightened interest surrounding these developments.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after news of a multi-year AI compute deal with OpenAI, including potential stock warrants, fueled bullish sentiment. Community members are discussing the potential impact on market share and revenue, with some analysts raising price targets significantly. The conversation highlights a possible shift in the AI chip landscape and increased competition for Nvidia.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to speculation of a potential partnership with Tesla, sparked by a teaser video featuring Archer's eVTOL aircraft alongside Tesla's Optimus robot. The community is actively discussing potential price targets and the likelihood of a formal announcement from either company. Broader interest in the eVTOL sector and Archer's existing partnerships are also contributing to the buzz.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Fueled by community enthusiasm, Rigetti Computing is trending as retail investors discuss the potential for a short squeeze and the broader implications of quantum computing's advancements. Some traders are closely watching the stock's momentum, while others express concern about its high valuation relative to revenue. Discussions also touch on Rigetti's place in the quantum computing race against competitors like IBM and Google.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending amid discussions around a potential crypto launch and expansion into new financial services, sparking bullish sentiment among investors. Community members are weighing in on the company's growth prospects and comparing it to competitors, while some anticipate a short squeeze. Technical analysis suggests key support and resistance levels are being closely monitored as traders assess the stock's momentum.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the nostalgia of internet rage comics and memes. Community members express excitement, referencing potential 'moonshot' gains and emphasizing the strength of the growing community. The coin is seen as a revival of early internet culture, embodying the raw, chaotic energy of the original memes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM).The Summit Part 2 trial met its primary endpoint with a statistically significant placebo-adjusted improvement of 8.91 points in total symptom score (TSS) at 24 weeks.&nbsp;Patients treated with bezuclastinib saw a mean TSS reduction of 24.3 points, compared to 15.4 points for placebo.&nbsp;The drug also met all key secondary endpoints, including reductions in serum tryptase, with 87.4% of treated patients achieving at least a 50% drop versus none in the control group.&nbsp;Most adverse events were low-grade. Discontinuations due to side effects occurred in 5.9% of patients, all of whom recovered.H.C. Wainwright raised its price target to $22 from $12 and maintained a 'Buy' rating, raising its approval probability estimate to 95% from 60%, calling bezuclastinib a potential new standard of care.&nbsp;Jefferies lifted its target to $28 from $23 with a 'Buy' rating, citing a “home run” outcome and a $1 billion market opportunity in ISM alone.Leerink increased its target to $18 from $16 and reiterated an 'Outperform' rating, noting the safety profile exceeded expectations and pointing to strong positioning ahead of the Peak and Apex trial readouts due later in 2025.&nbsp;Baird took a more conservative view, raising its target to $9 from $7 while maintaining a 'Neutral' rating, stating that the results were better than the worst-case scenario but fell short of the best.Cogent remains on track to submit a new drug application (NDA) for bezuclastinib by year-end 2025 and will present detailed Summit findings at a medical conference later this year.Separately, Cogent announced a proposed public offering of $150 million in common stock.&nbsp;The company said proceeds will support continued development, regulatory and commercial preparation for bezuclastinib and other pipeline candidates, as well as general corporate purposes.&nbsp;On Stocktwits, retail sentiment for Cogent was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/COGT">Cogent’s stock</a> has risen 25.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple firms raised their price targets on Cogent Biosciences (COGT) following strong results from the Phase 3 Summit trial of bezuclastinib/Photo credit: Getty Images

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Equity

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options

Investors eyeing a purchase of Cogent Biosciences Inc (COGT) stock, but tentative about paying the going market price of 6.62/share, might benefit from considering selling puts among the...

Cogent Biosciences (COGT, $6.9) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that COGT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cogent Biosciences (COGT, $6.9) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that COGT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Cogent Biosciences files to sell 31.2M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cogent Biosciences (COGT, $6.72) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling COGT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cogent Biosciences (COGT, $6.72) Stochastic Oscillator left the oversold zone on March 28, 2024

This is a signal that COGT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.52	--	--	N/A
Q2 '25	-$0.59	--	--	N/A
Q1 '25	-$0.60	-$0.64	-5.48%	MISSED
Q4 '24	-$0.60	--	--	N/A
Q3 '24	-$0.57	-$0.64	-13.04%	MISSED

COGT
Cogent Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest COGT News

COGT Cogent Biosciences Inc